PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19286961-2	2009	We further hypothesized that PKG-dependent activation of survival kinase ERK may play a causative role in sildenafil-induced cardioprotection via induction of endothelial nitric oxide synthase (eNOS)/inducible nitric oxide synthase (iNOS) and Bcl-2.	Sildenafil Citrate	106-116	B cell leukemia/lymphoma 2	Mus musculus	243-248	
21398594-6	2011	Western blot analysis showed enchanced Bcl-2-to-Bax ratio with sildenafil treatment (P < 0.05 vs. saline).	Sildenafil Citrate	63-73	B cell leukemia/lymphoma 2	Mus musculus	39-44	
19286961-9	2009	Western blots revealed that sildenafil significantly increased phosphorylation of ERK1/2 and GSK-3beta and induced iNOS, eNOS, Bcl-2, and PKG activity in the heart 24 h after treatment.	Sildenafil Citrate	28-38	B cell leukemia/lymphoma 2	Mus musculus	127-132	
19286961-12	2009	We conclude that these studies provide first direct evidence that PKG-dependent ERK phosphorylation is indispensable for the induction of eNOS/iNOS and Bcl-2 and the resulting cardioprotection by sildenafil.	Sildenafil Citrate	196-206	B cell leukemia/lymphoma 2	Mus musculus	152-157	
18723505-10	2008	Sildenafil also enhanced the Bcl-2/Bax ratio, phosphorylation of Akt, ERK1/2, and glycogen synthase kinase 3beta.	Sildenafil Citrate	0-10	B cell leukemia/lymphoma 2	Mus musculus	29-34	
15811867-11	2005	Bcl-2 was decreased in the doxorubicin group but was maintained at basal levels in the sildenafil+doxorubicin group.	Sildenafil Citrate	87-97	B cell leukemia/lymphoma 2	Mus musculus	0-5	
33856030-5	2021	KEY FINDINGS: It was shown that sildenafil significantly increased the levels of cGMP and Caspase-3 with a reduction of NF-kappaB, Bcl-2, Cyclin D1, intercellular adhesion molecule 1, matrix metalloproteinase-2 levels and normalisation of Nrf2 along with pronounced improvement in the histological patterns.	Sildenafil Citrate	32-42	B cell leukemia/lymphoma 2	Mus musculus	131-136	
15668244-8	2005	An early increase in Bcl-2 to Bax ratio with sildenafil treatment was also observed in myocytes after SI-RO.	Sildenafil Citrate	45-55	B cell leukemia/lymphoma 2	Mus musculus	21-26	
15668244-9	2005	The increase of Bcl-2 expression by sildenafil was inhibited by nitric-oxide synthase (NOS) inhibitor, L-nitro-amino-methyl-ester.	Sildenafil Citrate	36-46	B cell leukemia/lymphoma 2	Mus musculus	16-21	
15668244-12	2005	The up-regulation of Bcl-2 expression by sildenafil was also absent in iNOS-deficient myocytes.	Sildenafil Citrate	41-51	B cell leukemia/lymphoma 2	Mus musculus	21-26	
33856030-6	2021	CONCLUSIONS: These results indicated that sildenafil markedly induces cell cycle arrest, apoptosis and inhibits the metastatic activity through activation of cyclic guanosine monophosphate/protein kinase G pathway and down-regulation of cyclin D1 and nuclear factor kappa light chain enhancer of activated B cells with downstream anti-apoptotic gene Bcl-2, which underscores the critical importance of future using sildenafil in the treatment of lung cancer.	Sildenafil Citrate	42-52	B cell leukemia/lymphoma 2	Mus musculus	350-355	
32535704-9	2020	Co-ingestion with sildenafil blunted the alcohol-induced increase in miR-214, ERK1/2 phosphorylation, and maintained Bcl-2 and decreased PARP cleavage levels.	Sildenafil Citrate	18-28	B cell leukemia/lymphoma 2	Mus musculus	117-122